Bright Horizons’ Post

World Patient Day: Sanofi's Dedication to Putting Patients First. Every voice matters on #WorldPatientDay. At Sanofi, we are more than just a pharmaceutical company – we are partners in the healthcare journey. From healthcare professionals to advocacy groups, patients are at the heart of everything we do. We believe their insights are crucial for developing effective solutions and shaping a better future for healthcare. 𝐓𝐡𝐢𝐬 𝐲𝐞𝐚𝐫, 𝐰𝐞 𝐜𝐞𝐥𝐞𝐛𝐫𝐚𝐭𝐞 𝐨𝐮𝐫 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐝 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐡𝐫𝐨𝐮𝐠𝐡: • 𝐒𝐭𝐫𝐨𝐧𝐠 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐰𝐢𝐭𝐡 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝟕𝟎 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐚𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐦𝐩𝐚𝐜𝐭𝐢𝐧𝐠 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝟏𝟎𝐤 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬: We recognize their invaluable role in connecting with and empowering patients. • 𝐓𝐡𝐞 𝐒𝐚𝐧𝐨𝐟𝐢 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐂𝐡𝐚𝐫𝐭𝐞𝐫: Read about our concrete actions and 2023 results in supporting patients and caregivers • 𝐀 𝐬𝐡𝐚𝐫𝐞𝐝 𝐯𝐢𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞: We envision a world where healthcare is a collaborative effort fueled by understanding and compassion. Join us in building a future where every patient thrives. Share your thoughts and experiences in the comments below! #SanofiCommitment #PatientCenteredCare Helena Freitas Marisol García Pulgar Francisco Nuno Rocha-Gonçalves Mariana Rasteiro

“Competitors will also have to start – now – creating capacity to compete to even give them a fighting chance to take any meaningful share from Eli Lilly and Company and Novo Nordisk in the future,” observes Trevor Polischuk, Ph.D., M.B.A. at the Worldwide Healthcare Trust. #Healthcare #Obesity #GrowthPortfolio Investments involve risks. The value of investments and income derived from them may go down as well as up and you may not receive back all the money which you invest. Past performance is no guarantee of future performance.

Chiesi Group celebrates €3bn sales success in 2023 With 31 affiliates globally, Chiesi Group has demonstrated its commitment to delivering tangible benefits for patients, people, and the planet, showcasing the efficacy of its operating model centered around shared value, sustainability, and high ethical standards. "The accelerated evolution experimented by the Chiesi Group in 2023 was consistent with our shared value approach. This means addressing social challenges and business opportunities together, fostering a culture of inclusion, respect, and empowerment among Chiesi Group's 7,000 teammates". The Chiesi Group CARE franchise, catering to specialty care, neonatology, and consumer healthcare, demonstrated consistent growth across regions, with sales up 2% at CER. Notable advancements included the development of a natural surfactant for premature newborns and agreements to address complications of extremely premature birth, underscoring the company's commitment to innovation and patient care. https://lnkd.in/eabQRQZ6 #PublicHealth #Europe #StayInformed #StayEmpowered

Simultaneous offloading of remaining stakes in their consumer health spin-offs by GSK (Haleon - 4.2%) and Johnson & Johnson (Kenvue - 9.5% stake) The move signals the Big Pharma's willingness to cut the ties from its recently spun-off Consumer Health divisions (more of a PR move than strategic, given the size of remaining stake vs the total size of the Pharma business/ market cap, hint: ~1%) The sale will allow Pharma players to sharpen its focus on its key growth drivers vaccines, cancer and infectious diseases. The long-term impact on the Haleon and Kenvue is yet to be seen, but initially the markets have perceived the move negatively for the spin-offs (drops for both Haleon and Kenvue) Exciting times ahead for CHC pure players, one of the most dynamic and interesting #cpg verticals 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀/ 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢𝘀 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #consumerhealth

This week, our policy team supporting The Public Sector HealthCare Roundtable - Andrew MacPherson, Tomas Bednar, and Victoria Russo - shared insights on voters' top concerns for the upcoming presidential election and the issues shaping public sector health care in 2024. From PBM reforms to pharmaceutical cost containment and potential Medicare Advantage changes, 2024 presents several policy opportunities and challenges for public sector purchasers and the workers they represent. Explore the Roundtable's 2023-2024 Policy Priorities and advocacy activities to stay up-to-date and informed: https://lnkd.in/eWGS9gWw #publicpolicy #healthcare #politics #publicsector #pharmaceuticals #MedicareAdvantage

🚀 Thrilled to share insights from the recent webinar on "Evidence Generation Strategies for Enhanced Market Access Success" hosted by Baker Tilly! With expert panelists (David Gregory, Arun Parekkat, Grace Macalino, Keith Needham, & Peter Bannister) from various corners of the healthcare and pharmaceutical industries, the discussion was rich with strategic advice. Key Takeaways: 1️⃣ Strategic Importance: Effective evidence generation is not just about supporting regulatory approval but is crucial for successful market access. It's about painting a clear picture of the product's impact, safety, and economic value. 2️⃣ Overcoming Challenges: The journey to market access is fraught with hurdles, from high development costs to stringent regulatory landscapes. It's imperative to navigate these with a robust evidence-backed strategy. 3️⃣ Stakeholder Engagement: Addressing the needs of multiple stakeholders simultaneously with your evidence strategy enhances both cost efficiency and effectiveness, making your case compelling to regulators, payers, and end-users alike. 4️⃣ Leveraging Real-World Evidence: Integrating real-world data with traditional clinical trials can provide more comprehensive insights, accelerating market access and improving ROI. 💡 As we navigate the complexities of bringing pharmaceutical innovations to market, let's continue pushing the boundaries of strategic evidence generation. Remember, it's about making informed decisions that ultimately benefit patient care and drive industry progress. Feel free to connect and discuss more on how we can leverage these strategies for a transformative impact! Here's a link to the webinar: https://lnkd.in/guY8npQE #MarketAccess #EvidenceGeneration #RealWorldEvidence

Directing this to the attention of #FDA #OHSU #NCCN: DPD testing - so easy, inexpensive and life-saving. Make DPD testing mandatory prior to starting #5FU and #XELODA.

Partnership will boost the vaccine Production.

Investing in Health Savings Accounts: Seize the Opportunity with Novo Nordisk Summary: Novo Nordisk, a leading healthcare company, has experienced an impressive surge in its shares, driven by the success of its popular weight-loss drug Wegovy. Despite this phenomenal growth, Novo Nordisk's stock continues to trade at a significant discount compared to its main U.S. competitor, Eli Lilly. This presents a compelling opportunity for investors looking to maximize their investment in the healthcare sector. Novo Nordisk has emerged as a dominant player in the pharmaceutical industry, particularly in the area of weight management solutions. With the increasing focus on health and wellness, the demand for effective weight-loss drugs is on the rise. Wegovy, Novo Nordisk's flagship product, has garnered significant attention and achieved remarkable sales growth since its launch. This success has translated into substantial gains for the company, with its stock soaring by over 350% since 2020. Despite these impressive achievements, Novo Nordisk's stock remains undervalued compared to its primary competitor, Eli Lilly. This discrepancy presents a unique opportunity for investors looking to capitalize on the growth potential of the healthcare sector. By investing in Novo Nordisk, individuals can tap into the company's strong market position, innovative product pipeline, and the ever-increasing demand for weight-management solutions. Don't miss out on the chance to grow your Health Savings Account while contributing to the well-being of individuals and families. Take action now, invest in Novo Nordisk, and experience the benefits of long-term investments in the healthcare industry. Together, we can achieve financial prosperity and support the pursuit of a healthier world. 💰💪🌍 #hsa #investing #healthcare #health #family #wellness